VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
VaxCT
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

4'F-6TF-MUC1(20)-TTox Conjugate Vaccine
Vaccine Information
  • Vaccine Name: 4'F-6TF-MUC1(20)-TTox Conjugate Vaccine
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Type: Conjugate vaccine
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Antigen: 20-mer 4?F-TF-Thr6-MUC1 glycopeptide (PAHGVTSAPETRPAPGSTAP) (Johannes et al., 2015)
  • Immunization Route: subcutaneous injection
  • Description: A synthetic fluorinated MUC1 glycopeptide-tetanus toxoid (TTox) conjugate vaccine comprising a 4'-deoxy-4'-fluoro-Thomsen–Friedenreich (4'F-TF) antigen incorporated at position 6 of a 20-mer MUC1 tandem repeat domain, conjugated via a squarate linker and triethylene glycol spacer. The 4'-fluoro substitution confers enhanced in vitro resistance to enzymatic degradation, with the 4'F-TF derivative remaining intact over 7 hours of β-galactosidase (bovine testes) incubation compared to 50% degradation of the native TF antigen within approximately 3 hours. Subcutaneous immunization of female Balb/cj mice (n=3) with CFA followed by two intraperitoneal IFA booster immunizations at 21-day intervals elicited strong tolerance-breaking immune responses, with serum antibody levels determined 5 days post-final immunization showing titers of ~1:40,000, along with strong anti-carrier (TTox) responses. Isotype analysis revealed predominant IgG1 induction with a smaller IgG2a/b fraction and virtually no IgM, indicating effective antibody class switching consistent with an MHC II-restricted response and establishment of immunological memory. Antisera were confirmed by FACS to cross-react with native MUC1 epitopes on MCF-7 human breast cancer cells (Johannes et al., 2015).
Host Response
References
Johannes et al., 2015: Johannes M, Reindl M, Gerlitzki B, Schmitt E, Hoffmann-Röder A. Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope. Beilstein journal of organic chemistry. 2015; 11; 155-161. [PubMed: 25670999].